Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Franklin Gaylis

Urology La Mesa, CA Medical Doctor

NPI 1750360806 CMS profile 125089

8851 Center Dr, La Mesa, CA 91942

Open in the dashboard

General payments

$81,472

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$2,561,257

6 holdings reported · through program year 2025

Research they led as principal investigator

$342,272 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Franklin Gaylis of La Mesa, CA is reported in the CMS Open Payments database as having received $81,472 across 99 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $342,272 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $2,561,257 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,466 9
2024 General $928 12
2023 General $18,355 18
2022 General $26,022 31
2021 General $1,912 7
2020 General $14,493 7
2019 General $15,298 15
2024 Ownership $637,107 2
2023 Ownership $624,631 1
2022 Ownership $301,546 1
2021 Ownership $280,007 1
2020 Ownership $717,966 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Franklin Gaylis
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Franklin Gaylis were reported at $4,466. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Franklin Gaylis Urology median Middle half National median
2019 $15,298 $480 $147–$1,201 $163
2020 $14,493 $246 $87–$645 $114
2021 $1,912 $358 $111–$1,000 $132
2022 $26,022 $476 $143–$1,263 $149
2023 $18,355 $560 $168–$1,461 $160
2024 $928 $563 $170–$1,464 $164
2025 $4,466 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $18,447 16 payments
  2. Janssen Scientific Affairs, LLC $15,736 3 payments
  3. Johnson & Johnson Health Care Systems Inc. $14,242 22 payments
  4. SN Holdings, LLC $11,543 14 payments
  5. UroGPO LLC $8,020 2 payments
  6. AstraZeneca Pharmaceuticals LP $4,399 6 payments
  7. Avyxa Pharma, LLC $4,056 7 payments
  8. Astellas Pharma US Inc $3,000 1 payment
  9. Dendreon Pharmaceuticals LLC $693 5 payments
  10. Sumitomo Pharma America, Inc. $402 5 payments
  11. Other $935 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $59,312 18 payments
  2. Travel and Lodging $8,823 20 payments
  3. Food and Beverage $5,526 53 payments
  4. Honoraria $4,750 3 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,050 4 payments
  6. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. LUPRON DEPOT Endocrinology $15,186 11 payments
  2. LYNPARZA $4,272 5 payments
  3. LUPRON DEPOT Endocrinology $3,038 2 payments
  4. XTANDI $3,000 1 payment
  5. PROVENGE $693 5 payments
  6. ORGOVYX $449 6 payments
  7. ERLEADA $283 3 payments
  8. BALVERSA $136 1 payment
  9. AKEEGA $136 1 payment
  10. Cysview $118 1 payment
  11. Other $424 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record